Abstract
Background: Atopic dermatitis (AD) is characterized by dysregulated immune responses and persistent inflammation. Regulatory B (Breg) cells suppress inflammation, but the metabolic mechanisms constraining their function in AD remain unclear. Objective: We sought to define whether immunometabolic regulation governs Breg cell differentiation and function in AD. Methods: Mouse and human B cells were stimulated with the adenosine monophosphate–activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) under inflammatory conditions, with genetic and pharmacologic perturbations. Functional and mechanistic analyses were performed with coculture systems, a 2,4-dinitrochlorobenzene and Dermatophagoides farinae extract–induced murine model of AD, adoptive transfer approaches, adoptive transfer, and human peripheral blood mononuclear cells from patients with AD. Results: AICAR treatment or adoptive transfer of AICAR-induced Breg cells significantly attenuated AD-like inflammation, whereas AMPK inhibition or IL-10 blockade abrogated these effects. Mechanistically, AICAR induced IL-10–producing Breg cells through AMPK-dependent suppression of mTOR signaling and mitochondrial reactive oxygen species while preserving oxidative phosphorylation. This reprogramming selectively enhanced regulatory B-cell function and suppressed STAT1 signaling without affecting STAT3. Functionally, these Breg cells suppressed TH1, TH2, and TH17 responses in an IL-10–dependent manner without expanding Foxp3+ regulatory T cells. In human peripheral blood mononuclear cells from patients with AD, AICAR restored immunometabolic coupling by increasing IL-10–producing B cells and reducing proinflammatory cytokine production. Conclusion: These findings identify an AMPK-mTOR-redox metabolic checkpoint that governs regulatory B-cell function and restrains AD inflammation, linking metabolic control to immune regulation.
| Original language | English |
|---|---|
| Journal | Journal of Allergy and Clinical Immunology |
| DOIs | |
| State | Accepted/In press - 2026 |
Keywords
- AMPK
- Atopic dermatitis
- B-cell regulation
- IL-10
- immunometabolism
- inflammation
- metabolic reprogramming
- mitochondrial reactive oxygen species
- mTOR
- regulatory B cells
Fingerprint
Dive into the research topics of 'AMPK-driven immunometabolic reprogramming enhances CD19+CD21hiCD24hi regulatory B-cell–mediated suppression of atopic dermatitis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver